News & Updates
Filter by Specialty:
Can rosuvastatin protect against chemo-induced cardiotoxicity in HER2+ breast cancer?
Use of rosuvastatin is associated with a significantly lower decline in left ventricular ejection fraction (LVEF) and lower serum levels of cardiotoxicity-associated biomarkers in newly diagnosed HER2-positive breast cancer patients treated with anthracycline-based chemotherapy followed by trastuzumab, according to the results of a prospective, randomized, controlled, parallel study.
Can rosuvastatin protect against chemo-induced cardiotoxicity in HER2+ breast cancer?
22 Jul 2024
Melphalan-prednisone-bortezomib improves HRQoL in intermediate-fit and frail NDMM patients
Treatment with melphalan-prednisone-bortezomib (MPV) improves health-related quality of life (HRQoL) in both intermediate-fit and frail newly diagnosed multiple myeloma (NDMM) patients, according to the results of the prospective phase II HOVON123 trial.
Melphalan-prednisone-bortezomib improves HRQoL in intermediate-fit and frail NDMM patients
22 Jul 2024
Over-the-counter supplement touted for improving walking distance in PAD
Nicotinamide riboside supplements show a signal of benefit for helping patients with lower extremity peripheral arterial disease (PAD) walk more
Over-the-counter supplement touted for improving walking distance in PAD
21 Jul 2024
Acute benign myositis may occur in kids with flu infection
Children with influenza A virus infection are susceptible to acute benign myositis (ABM), with most patients showing clinical characteristics consistent with postfebrile myalgia, reports a study.
